Dermatology

There is no consensus with regard to perioperative blood thinner management in patients undergoing cutaneous procedures. There are many studies that support continuation of blood thinners during cutaneous procedures supporting the conclusion that blood thinners should not be discontinued for cutaneous procedures.

Dermatitis herpetiformis is an autoimmune, pleiomorphic, papulovesicular disorder associated with celiac disease and gluten sensitivity. This article will provide a comprehensive review of Dermatitis herpetiformis, including its epidemiology, clinical and pathological findings, diagnostic evaluation, and management.

Update on Loratadine Dry Syrup 1% Claritin® Schering-Plough, Valacyclovir Hydrochloride TEVA Pharmaceutical Industries, and news about Anti-dandruff, anti-acne and anti-melanoma agents.

Key to the management of photodermatoses is photoprotection, which includes seeking shade; wearing wide brimmed hats, and sunglasses; and applying sunscreens. This article discusses sunscreens, sun protection, UVA, UVB, and its role in managing various skin conditions.

The latest drug & device update covers: Trifarotene 0.005% cream (Aklief®, Galderma), Afamelanotide implant (Scenesse®, Clinuvel Pharmaceuticals), Rituximab for IV use (Rituxan®, Genentech), Jynneos™ (Bavarian Nordic), Aczone® (Almirall) and Juvéderm Voluma® XC (Allergan)

There are no specific antipruritic drugs on the market, but there are a high number of case reports and experimental investigations describing medications with antipruritic potency. It is therefore the aim of this article to review the major systemic antipruritic drugs and give a short overview on the different types of pruritus.

Butenafine may be effective and safe in the treatment of interdigital tinea pedis (apply twice daily for 1 week or once daily for 4 weeks), tinea corporis/ tinea cruris (apply twice daily for 2 weeks), and pityriasis versicolor (apply once daily for two weeks).

Increased accumulation of AGEs in human tissue has been associated with serious medical concerns including end stage renal disease, chronic obstructive pulmonary disease, and, recently, skin aging. In this review, we summarize the evidence supporting the role of glycation in skin aging.

Update on Peginterferon alfa-2b (Sylatron™), Imiquimod 3.75% cream (Zyclara®), experienced recurrence 12 weeks after therapy. (Adapalene 0.1% + benzoyl peroxide 2.5% gel Tactuo™), Collagenase clostridium histolyticum (Xiapex®), and updates on generic drugs.

Update and discussion on onychomycosis (nail fungus) and Efinaconazole 10%. Recent clinical trial results, and discussion about patient safety profile, special cases like diabetic patients, and cure rates.

With so many new peel preparations on the market today, the dermatologist must ask himself basic questions concerning the products. The most important question is directed to the medical literature rather than the advertising or marketing campaign so common among marketdriven cosmetic products.

Pruritus, or itch, is a common sensation that causes a person to want to scratch. It is a complex process that may negatively impact quality of life. This overview provides information regarding the various management and treatment options for pruritus.

Update on: Etanercept Enbrel® Clindamycin 1%, Benzoyl Peroxide 5% BenzaClin™ Ethinylestradiol & Norethindrone Acetate Estrostep Desloratadine Aerius™ & Neoclarityn™ Agalsidase Alfa Replagal™ Ciprofloxacin Butenafine HCl Mentax®

Update on: Clobetasol propionate Olux Foam 0.05% Alitretinoin 0.1% gel Panretin Graftskin Apligraf Bexarotene 1% gel Targretin 10% Docosanol Cream Bleomycin ANDA

Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments.

The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the treatment of lung, pancreatic, head and neck, and colon carcinomas.

There is no clear evidence that monoclonal antibodies influence neurological function and modulate behavior in humans. More research in this area is necessary in order to begin to understand the potential effects of..

January and February 2016: Update on drugs, approval dates, and comments. Autologous cell suspension (ReCell® ReGenerCell® ReNovaCell®), Calcipotriene 0.005% + betamethasone dipropionate 0.064% foam (Enstilar®), Ipilimumab (Yervoy®), Talimogene laherparepvec (T-Vec) oncolytic virus therapy (Imlygic™), Cobimetinib + vemurafenib (Cotellic™ + Zelboraf®), Dabrafenib + trametinib (Tafinlar® + Mekinist®), Nivolumab injection (Opdivo®) are covered.

Certolizumab Pegol appears to offer a safe and effective psoriasis treatment for patients who are considering pregnancy, pregnant, or lactating based on its pharmacokinetics and available safety data.

Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.

Imiquimod 5% cream (Aldara™, Graceway Pharmaceuticals) is an immune response modifier used for the topical treatment of anogenital warts in non-HIV-infected patients. Several randomized controlled trials have demonstrated that imiquimod 5% cream is a safe and efficacious treatment.

While prominent ears are considered a sign of good fortune in the Far East, Western society looks upon prominent ears in a far less positive manner. Children with prominent ears are often the subjects of verbal and at times physical abuse by their peers, resulting in adverse psychological effects.

Toxicodendron dermatitis results from a reaction to an oil soluble oleoresin that is present in many parts of the poison ivy and poison oak plants. Prophylactic measures and treatments are discussed.

Benzoyl peroxide 5% plus erythromycin 3% (Benzamycin. gel, Dermik) will be evaluated. Although it is not known how effective it is compared with benzoyl peroxide and erythromycin prescribed separately, Benzamycin® is simpler to use and likely to improve patient compliance.

Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).

Scalp psoriasis, especially around the hairline, can cause significant impairment in quality of life due to its visibility. This articles makes a case for a combination of 308 nm excimer laser with clobetasol spray for the treatment of scalp psoriasis.

Herbs have been used in clinical medicine for thousands of years. However, it is only in recent times that we have been able to employ scientific methods to prove the efficacy of many of these herbs and to give us a better understanding of their mechanisms of action.

Update on Peginterferon alfa-2b PEG-Intron™, Elesclomol (formerly STA-4783), Hyaluronic Acid Gel + Lidocaine Prevelle Silk™.

Updates on: Tigecycline Tygacil™ Terbinafine HCl Lamisil® Tablets Moxifloxacin HCl Avelox® Adalimumab Humira®

Most people with mild-to-moderate psoriasis manage their disease with topical therapies. However, adherence to topical treatment remains a challenge.. Read about new topical therapeutic options.

Atopic dermatitis is a chronic inflammatory skin disease affecting children and adolescents worldwide. This articles reviews the potential relationship of atopic dermatitis to diet and the effectiveness of elimination diets and diet supplementation in the management of AD.

Update covering: Benzoyl peroxide 5% cream, Isotretinoin ointment, Tapinarof 1% cream, Baricitinib tablets, and Dupilumab for SC injection.

Disorders of hyperpigmentation are difficult to treat, particularly in dark-skinned individuals. The goal is to reduce the hyperpigmentation without causing undesirable hypopigmentation or irritation in the surrounding normally pigmented skin. The psychosocial impact caused by these disorders must be considered.

Update on Ketoconazole 2% Gel Xolegel™, Infliximab Remicade®, Quadrivalent Human Papillomavirus Recombinant Vaccine Gardasil™, Desonide Verdeso™ Foam 0.05% and drug news about melanoma and anti-acne agents.

Onychomycosis is one of the most common nail disorders. Despite recent therapeutic advances with the introduction of effective systemic agents and transungual drug delivery systems, the incidence of onychomycosis is increasing.

Psoriasis is a common dermatosis, affecting children in North America. Many papers have stressed the treatments available for adult psoriasis, but few have dealt with this disorder in children. Topical treatment modalities continue to be the first line therapy for childhood psoriasis.

Moisturizers are widely used products that are important in many dermatologic and cosmetic skin therapies. They contain varying combinations of emollients, occlusives, and humectants to achieve their beneficial effects, and there is an overwhelming number of formulations available.

Psoriasis represents a potentially life-altering disease that can profoundly impact physical, emotional and social functioning, and overall quality of life. Part I of this 2-part series will focus on topical agents, their varying degrees of effectiveness, potential side-effects and applications in clinical practice.

February 2013: Update on drugs, approval dates, and comments. Varicella zoster immune globulin (human) injection (Varizig®), Lidocaine 7% + tetracaine 7% cream (Pliaglis®), Isotretinoin capsule (Epuris™) are covered. Devices such as Laser hair therapy iGrow® Hair Growth Platform and LED device for acne Celluma™ are also covered.

Latest drug update covers Belimumab for IV use (Benlysta, GSK), Etanercept-ykro (Eticovo®, Samsung Bioepis), Halobetasol propionate 0.01% + tazarotene 0.045% lotion (Duobrii™, Bausch Health), Protein replacement therapy for SC injection (PTR-01, Phoenix Tissue Repair), Risankizumab for SC injection (Skyrizi™, AbbVie), Ruxolitinib tablets (Jakafi®, Incyte Corporatio), and Oral MEK inhibitor (PD-0325901, SpringWorks Therapeutics).